An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
Version of Record online: 8 JAN 2010
© 2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Value in Health
Volume 13, Issue 4, pages 346–357, June/July 2010
How to Cite
Ray, J. A., Carr, E., Lewis, G. and Marcus, R. (2010), An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK. Value in Health, 13: 346–357. doi: 10.1111/j.1524-4733.2009.00676.x
- Issue online: 30 JUN 2010
- Version of Record online: 8 JAN 2010
- 2GLOBOCAN. 2002 database. Available from: http://www-dep.iarc.fr/GLOBOCAN_frame.htm[Accessed May 19, 2008.
- 3Cancer Research UK. UK Non-Hodgkin lymphoma incidence statistics. Available from: http://info.cancerresearchuk.org/cancerstats/types/nhl/incidence/#source8[Accessed December 4, 2008.
- 6National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—version 1. 2005: non-Hodgkin's Lymphoma. Available from: http://www.nccn.org[Accessed April 4, 2008.
- 9Rituximab as Third-Line Treatment of Refractory or Recurrent Stage III or IV Follicular Non-Hodgkin's Lymphoma. Birmingham: University of Birmingham, Department of Public Health and Epidemiology, 2001., , , et al.
- 10European Medicines Agency (EMEA). Mabthera Summary of Product Characteristics (2008). Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Mabthera/emea-combined-h165en.pdf[Accessed December 4, 2008.
- 11Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–92., , , et al.
- 13Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) significantly improves the outcomes for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Study Group. Blood 2005;106:3725–32., , , et al.
- 14Update of the FL 2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma patients. J Clin Oncol 2006;24(Suppl. 18):S7508., , , et al.
- 15National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004.
- 17Scottish Medicines Consortium, NHS Scotland. Rituximab: New Product Assessment. Available from: http://www.scottishmedicines.org.uk/smc/files/Microsoft%20Word%20%20rituximab%20MabThera%20FINAL%20May%202009.pdf, 2007 [Accessed November 26, 2009.
- 20Decision Modelling for Economic Evaluation. Oxford: Oxford University Press, 2006., , .
- 21Office for National Statistics. Statistical Bulletin Consumer Price Indices. Available from: http://www.statistics.gov.uk/pdfdir/cpi0109, 2009 [Accessed February 2, 2009.
- 23Economic Aspects of Non-Hodgkin's Lymphoma. London, UK: Office of Health Economics, 1998., , , .
- 24UK Department of Health. National Health Service Reference Costs (2006/07). London: Department of Health. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571[Accessed February 2, 2009.
- 25Modelling Survival Data in Medical Research (2nd ed.). Boca Raton, FL: Chapman & Hall/CRC, 2003..
- 26Scotland and Newcastle Lymphoma Group. SNLG@ed.ac.uk: Database analysis (Roche data on file) 2004.
- 27The human mortality database. Available from: http://www.mortality.org[Accessed April 18, 2008., .
- 29MIMS. Monthly index of medical specialties. Available from: http://www.healthcarerepublic.com/mims[Accessed April 10, 2007.
- 30National Institute for Clinical Excellence. Technology appraisal 110. Rituximab for the treatment of follicular lymphoma. September 2006. Available from: http://www.nice.org.uk/guidance/TA110[Accessed February 2, 2009.
- 31Rituximab for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004;8:1–ix, 1–82., , , .
- 32Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2003., , , et al.
- 34Changing the problem to fit the solution: Johannesson and Weisteins (mis)application of economics to real world problems. J Health Econ 1193:469–76., .
- 37A cost-utility of maintenance rituximab for the treatment of relapsed/refractory follicular non-lymphoma (NHL) in the UK. ISPOR 10th Annual European Congress October 20–23, 2007, Dublin, Ireland. Abstract PCN46., , , .
- 39The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc., 1980., .